Navigation Links
BioTrends Prepares to Field ChartTrends(TM) Reports to Cover the Use of Biologic Agents in Psoriasis and Rheumatoid Arthritis
Date:3/16/2009

EXTON, Pa., March 16 /PRNewswire/ -- BioTrends Research Group, Inc. has been covering the biologics market for Psoriasis and RA through its TreatmentTrends(TM) series which are syndicated primary research reports based on self reported survey data collected from Dermatologists and Rheumatologists. The company is now expanding these offerings in the form of ChartTrends(TM) reports which aim to compare self-reported treatment patterns with actual patient level data.

The ChartTrends(TM) reports will each offer comprehensive insight into the management and use of biologics used in the treatment of Rheumatoid Arthritis (RA) and Psoriasis. Each report is derived from analysis of actual patient chart data and laboratory results collected from over 1,000 RA and Psoriasis patients currently being treated with biologics. The retrospective audit captures a wide range of patient demographic data, the range of dose variability, co-morbidities, concomitant medications, and laboratory values for the past year. Medication changes and actions taken during office visits are highlighted to understand the triggers for therapy initiation and adjustment. The final report also compares the self-reported practice patterns with actual patient records in order identify gaps in care.

These studies are being undertaken to understand the treatment algorithm for biologic initiation, how each of the biologic brands is typically used, what triggers brand switching, and what patient characteristics (age, co-morbidities, insurance type) influence treatment decisions. Additionally, the study will assess familiarity and interest in several late stage biologics in development (Roche's ACTEMRA, Centocor's SIMPONI, and UCB's CIMZIA in RA and Centocor's STELARA and Abbott's ABT-874 in Psoriasis). BioTrends, which has been offering ChartTrends(TM) reports since 2005, plans to publish the findings in June.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Study by BioTrends Highlights Practice Management Shifts Among Canadian Nephrologists
2. As SEIU Prepares Hostile Takeover of United Healthcare Workers, Surveillance of Local Union Office Ends in Assault by Off-Duty Police Officer
3. SCAIs Annual Fall Fellows Course Prepares New Interventional Cardiologists to Work in the Field
4. Irvine Pharmaceutical Services Enhances Staff, Prepares for Innovative Expansion
5. CytoDyn, Inc. Prepares for New Clinical of Its First-In-Class Drug for Treating HIV/AIDS
6. Gilbert Hospital Prepares for Flu Season
7. American Red Cross Prepares for Tropical Storm Fay in Florida
8. New Anti-Cellulite Treatment Prepares Women for Falls Short Skirts
9. New Anti-Cellulite Treatment Prepares Women for Warmer Weather and Beyond
10. First Ever National Biovigilance Network in the U.S. Reaches $1 Million in Funding, Prepares for Fall Pilot Launch
11. OrthoSynetics(TM) Expands Sales Team; Prepares to Grow
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... 06, 2016 , ... The Behavioral Health Center of Excellence ... organization as a top behavioral service provider in the country. The award celebrates ... satisfaction and qualifications, and consumer satisfaction. These areas are measured via a wide-ranging ...
(Date:12/6/2016)... ... December 06, 2016 , ... Experimentation involving human stem ... largely due to its potential for revolutionizing human disease treatment. There are multiple ... pluripotent stem cells (hiPSCs). , Both platforms have distinct advantages and disadvantages, ...
(Date:12/6/2016)... ... 06, 2016 , ... METTLER TOLEDO has launched its online ... white papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, brochures, datasheets, user ... documents, webinars and videos available online, visit the METTLER TOLEDO Expertise Library ...
(Date:12/6/2016)... ... ... 'Tis the season for family, festivity, food and fun! Temptation abounds, and ... eating healthy, staying active, and taking medication and doing daily foot health checks (a ... "Shopping trips, parties and family gatherings can take their toll on our feet during ...
(Date:12/6/2016)... B.C., Canada (PRWEB) , ... December 06, 2016 ... ... (STC) announce the availability of the newly updated International Audit Protocol Consortium (IAPC) ... use IAPC EHS audit protocols to understand the scope of their EHS regulatory ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Nov. 29, 2016 Several leading Alzheimer,s ... Accera, Inc. at 11 a.m. EST on ... Conference on Clinical Trials for Alzheimer,s Disease (CTAD). The ... in Alzheimer,s disease and therapeutic targets that address deficient ... "Following the recent failure of another therapy targeting the ...
(Date:12/5/2016)... , Dec 5, 2016 Research ... Market by Product (Instruments, Consumables), Application (Biomedical & Biochemical Research, Disease ... - Global Forecasts to 2021" report to their offering. ... , , ... USD 730.7 Million in 2021 from USD 574.8 Million in 2016, ...
(Date:12/5/2016)... PUNE, India , December 5, 2016 ... Market by Product Type and by Application - Global Opportunity Analysis and Industry ... in 2015, and is expected to reach $5,255 million by 2022, growing at ... market in 2015 with more than four-fifths share. ... ...
Breaking Medicine Technology: